Tel: +86 (0)571 8102-5280 Email:
219311-44-1 | Dabuzalgron

Dabuzalgron NLT 98%

SKU : MC541378

CAS Number : 219311-44-1

Molecular Formula : C12H16ClN3O3S | Molecular Weight : 317.79

Synonyms : Ro 115-1240

Quote Request
Purity NLT 98%
Storage at 20ºC 2 years

* The above information is for reference only.

* If the product has intellectual property rights, a license granted is must or contact us.

Chemical Name Dabuzalgron
CAS Number 219311-44-1
MDL Number MFCD13195546
Molecular Formula C12H16ClN3O3S
Molecular Weight 317.79
Synonyms Ro 115-1240
Introduction of 219311-44-1 :

Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function[1]. IC50 & Target: α-1A adrenergic receptor[1] In Vitro: Dabuzalgron treatment increases ERK phosphorylation in a dose-dependent fashion with an EC50 of 4.8 μM. ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron[1].
Dabuzalgron (10 μM; 4 hours) protects NRVMs from cell death due to Doxorubicin (DOX)[1].
Activation of the α1A-AR with Dabuzalgron (10 μM; 4 hours) mitigates the detrimental effects of DOX on mitochondrial membrane potential and abrogates the activation of important elements of the apoptotic response to mitochondrial damage[1]. In Vivo: Dabuzalgron (10 μg/kg; oral gavage; twice daily; for 7 days; C57Bl6J wild-type or α1A-AR knockout mice) treatment protects against DOX cardiotoxicity by activating the α1A-AR. Dabuzalgron protects against the reduction in transcripts related to mitochondrial function, up-regulates PGC1α, preserves ATP content, and reduces oxidative stress in the hearts of mice treated with DOX[1].

Related Products